Revenues leap at Oxford Pharmascience
Oxford Pharmascience saw revenues jump in the first half after it signed a sales deal with one of Brazil's largest pharmaceutical companies.
Oxford Pharmascience saw revenues jump in the first half after it signed a sales deal with one of Brazil's largest pharmaceutical companies.
Revenues came in at £341,000, up from £20,000 the year before, with sales to Brazil's Ach making up the lions share.
The pharmaceutical technology company cut its pre-tax loss to £399,000, from £501,000 in the first half of 2011, with loss per share coming in at 0.07p.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Chairman David Norwood said 2011 was a breakthrough year for the company having changed its focus to the higher value pharmaceutical market.
"The commencement of sales to Ach, one of Brazil's largest pharmaceutical companies and the launch of its OXP zero taste masking technology left [the company] well placed going into this year," he said.
-
Are you being haunted by the ghost of Christmas past? How festive cutbacks could boost your long-term wealthThe average family spends around £1,000 over the Christmas season. Here’s how much you could have gained if you had invested some of the money instead.
-
5 investment trusts for your pensionInvestment trusts are often a good choice for long term growth and income options, but which ones should you consider for your pension?
